Join Growin Stock Community!
Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-breakdown-chart

LLY Revenue by Segments

Revenue by SegmentsRevenue by Segments

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, Cardiometabolic Health generated the largest segment revenue at $15.8M, followed by Oncology at $2.3M, Immunology at $1.2M, Neuroscience at $0.4M, and Other at $0.2M. From Q2'23 to Q1'26, Cardiometabolic Health exhibited the strongest growth trajectory, rising from $5.0B to a peak of $14.4B in Q4'25 before the sharp Q1'26 decline, while Oncology and Immunology showed steady upward trends with Oncology reaching $2.6B in Q4'25; Neuroscience and Other segments remained relatively stable with minor fluctuations, and all segments experienced significant drops in Q1'26 with values falling to single-digit millions.